Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma

MedPage Today) — CHICAGO — Progression-free survival (PFS) was significantly higher with belantamab mafodotin (belamaf; Blenrep) combined with pomalidomide (Pomalyst) and dexamethasone (BPd), compared with standard-of-care pomalidomide, bortezomib…